Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Basics of Compounding: The "Negative" List

Author(s):  Allen Loyd V

Issue:  Jul/Aug 2015 - Volume 19, Number 4
View All Articles in Issue

Page(s):  311-313

Basics of Compounding: The
Basics of Compounding: The
Basics of Compounding: The

Download in electronic PDF format for $75

Abstract:  H.R. 3204 requires the formation of a Pharmacy Compounding Advisory Committee to address the following: The “Negative List”; The “Positive List of Active Pharmaceutical Ingredients”; and “Demonstrable Difficulties in Compounding.” At the first meeting of the Pharmacy Compounding Advisory Committee, the Committee addressed the drug products that have been withdrawn or removed from the market and cannot be compounded because they have been found to be unsafe or not effective. This article provides a current list of drugs that cannot be used in compounding, as well as a “kit” where the combination of ingredients/products cannot be compounded.

Related Keywords: Loyd V. Allen, Jr., PhD, RPh, do not compound list, U.S. Food and Drug Administration, FDA, Drug Quality and Security Act, Pharmacy Compounding Advisory Committee, drug safety

Related Categories: LEGAL, DISCONTINUED FORMULATIONS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Nov/Dec 2016
Pg. 457-458

Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Allen Loyd V Jr
Sep/Oct 2015
Pg. 389-390

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
Basics of Compounding: The "Negative" List
Allen Loyd V
Jul/Aug 2015
Pg. 311-313

U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing
Allen Loyd V Jr
Mar/Apr 2018
Pg. 92

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

The "Lists": What Do They Mean?
Voliva John
Nov/Dec 2016
Pg. 477-479

Standing Together Fixing the Drug Quality and Security Act
Miller David G
Mar/Apr 2015
Pg. 104-106

Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Cabaleiro Joe
Sep/Oct 2021
Pg. 358-362

The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List")
Allen Loyd V Jr
, Ashworth Lisa D
Jan/Feb 2005
Pg. 44-46

Basics of Compounding: The Revised "Not to Compound List"
Allen Loyd V Jr
Jan/Feb 2015
Pg. 57-58

U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
Mar/Apr 2017
Pg. 95-102

Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Blankenship Cynthia E
Sep/Oct 2014
Pg. 379-380

Applying Quality of Design Concepts to Pharmacy Compounding
Timko Robert J
Nov/Dec 2015
Pg. 453-463

U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013
Miller David G
Jan/Feb 2014
Pg. 35-36

The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Miller David G
May/Jun 2014
Pg. 208

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

Return to Top